Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Federal Trade Commission
Express Scripts
Cipla
Chubb
Fish and Richardson
Citi
Johnson and Johnson
US Department of Justice
Medtronic

Generated: October 22, 2017

DrugPatentWatch Database Preview

Details for Patent: 9,278,105

« Back to Dashboard

Which drugs does patent 9,278,105 protect, and when does it expire?


Patent 9,278,105 protects MINOCIN and is included in one NDA.

This patent has twenty patent family members in twenty countries.

Summary for Patent: 9,278,105

Title:Tetracycline compositions
Abstract: The present invention relates to compositions, pharmaceutical compositions, and methods for preparing the same, comprising a tetracycline with improved stability and solubility. Some embodiments include a tetracycline with an excess of a divalent or trivalent cation.
Inventor(s): Griffith; David C. (San Marcose, CA), Boyer; Serge (San Diego, CA), Dudley; Michael N. (San Diego, CA), Hecker; Scott (Del Mar, CA)
Assignee: Rempex Pharmaceuticals, Inc. (San Diego, CA)
Application Number:13/654,018
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Rempex Pharms Inc
MINOCIN
minocycline hydrochloride
INJECTABLE;INJECTION050444-001Approved Prior to Jan 1, 1982RXYesYes► Subscribe► Subscribe METHOD OF TREATING BACTERIAL INFECTIONS
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 9,278,105

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,084,802Tetracycline compositions► Subscribe
9,744,179Tetracycline compositions► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 9,278,105

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia2011252919► Subscribe
Brazil112012028524► Subscribe
Canada2799079► Subscribe
Chile2012003168► Subscribe
China102970992► Subscribe
Colombia6650346► Subscribe
Denmark2568987► Subscribe
European Patent Office2568987► Subscribe
European Patent Office3135289► Subscribe
Spain2613738► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Novartis
Covington
Baxter
Chubb
Cerilliant
QuintilesIMS
Julphar
Chinese Patent Office
US Army
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot